详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing

123| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Hosp 3,Canc Ctr,Shanxi Acad Med Sci, Taiyuan, Shanxi, Peoples R China [2]Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Hosp 3,Dept Hematol, Taiyuan, Shanxi, Peoples R China [3]Shanxi Acad Med Sci, Shanxi Bethune Hosp, Sino German Joint Oncol Res Lab, Taiyuan, Shanxi, Peoples R China [4]Duke Univ, Med Ctr, Div Hematopathol, Durham, NC USA [5]Duke Canc Inst, Durham, NC USA [6]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China [7]Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Hubei, Peoples R China

出处：

DOI：

ISSN：

关键词： CAR-T hematological malignancies mechanism novel strategies overcome resistance

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2020]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 7.561 出版当年[2020版] 7.624 出版当年五年平均 5.085 出版前一年[2019版] 8.787 出版后一年[2021版]

第一作者：

第一作者单位： [1]Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Hosp 3,Canc Ctr,Shanxi Acad Med Sci, Taiyuan, Shanxi, Peoples R China [2]Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Hosp 3,Dept Hematol, Taiyuan, Shanxi, Peoples R China [3]Shanxi Acad Med Sci, Shanxi Bethune Hosp, Sino German Joint Oncol Res Lab, Taiyuan, Shanxi, Peoples R China

通讯作者：

通讯机构： [2]Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Hosp 3,Dept Hematol, Taiyuan, Shanxi, Peoples R China [3]Shanxi Acad Med Sci, Shanxi Bethune Hosp, Sino German Joint Oncol Res Lab, Taiyuan, Shanxi, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China [7]Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Hubei, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]CAR T Cell Therapy for Hematological Malignancies [2]Erratum to: CAR T Cell Therapy for Hematological Malignancies. [3]CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies [4]CAR T Cell Therapy for Hematological Malignancies (vol 39, pg 874, 2019) [5]Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies [6]血液恶性肿瘤CAR-T治疗后患者报告结局的范围综述 [7]Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era [8]CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges [9]Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies [10]CAR⁃T免疫疗法在血液系统恶性肿瘤病人中的应用进展